Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193125-26-132644
Filing Date
2026-03-30
Accepted
2026-03-30 19:22:50
Documents
1
Period of Report
2026-03-26

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3455
  Complete submission text file 0001193125-26-132644.txt   4991
Mailing Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107
Business Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107 206.588.0256
ATOSSA THERAPEUTICS, INC. (Issuer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107
Business Address
Daniel Mark James (Reporting) CIK: 0002092593 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35610 | Film No.: 26816004